How many steps along the path is too far?

Clinical Infectious Diseases

Volumn 50, Issue 1, 2010, Pages 37-39

  Drusano, G L ^a  

^a ORDWAY RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VORICONAZOLE;

AREA UNDER THE CURVE; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG EXPOSURE; HUMAN; MONTE CARLO METHOD; NOTE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; UNSPECIFIED SIDE EFFECT;

ANTIFUNGAL AGENTS; CHILD; HUMANS; MYCOSES; PYRIMIDINES; TRIAZOLES;

EID: 72049101508     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/648680     Document Type: Note

References (16)

1. Neely M, Rushing T, Kovacs A, Jelliffe R, Hoffman J. Voriconazole pharmacokinetics and pharmacodynamics in children. Clin Infect Dis 2010; 50:27-36 (in this issue).
2. Denning DW, Ribaud P, Milpied N, et al. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis 2002; 34:563-571 (Pubitemid 34165316)
3. Pascual A, Calandra T, Bolay S, et al. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin Infect Dis 2008; 46: 201-211 (Pubitemid 351269158)
4. Smith J, Safdar N, Knasinski V, et al. Voriconazole therapeutic drug monitoring. Antimicrob Agents Chemother 2006; 50:1570-1572
5. Tan K, Brayshaw N, Tomaszewski K, Troke P, Wood N. Investigation of the potential relationships between plasma voriconazole concentrations and visual adverse events or liver function test abnormalities. J Clin Pharmacol 2006; 46:235-243 (Pubitemid 43146453)
6. Louie A, Drusano GL, Banerjee P, et al. Pharmacodynamics of fluconazole in a murine model of systemic candidiasis. Antimicrob Agents Chemother 1998; 42:1105-1109 (Pubitemid 28227905)
7. Andes D, Marchillo K, Stamsted T, Conklin R. In vivo pharmacokinetics and pharmacodynamics of a new triazole, voriconazole, in a murine candidiasis model. Antimicrob Agents Chemother 2003; 47:3165-3169
8. Andes D. In vivo pharmacodynamics of antifungal drugs in treatment of Candidiasis. Antimicrob Agents Chemother 2003; 47: 1179-1186 (Pubitemid 36368572)
9. Kashuba AD, Nafziger AN, Drusano GL, and Bertino JS, Jr. Optimizing aminoglycoside therapy for nosocomial pneumonia caused by gram-negative bacteria. Antimicrob Agents Chemother 1999; 43:623-629
10. Rybak MJ, Abate BJ, Kang SL, Ruffing MJ, Lerner SA, Drusano GL. Prospective evaluation of the effect of an aminoglycoside dosing regimen on rates of observed nephrotoxicity and ototoxicity. Antimicrob Agents Chemother 1999; 43:1549-1555
11. Lodise TP, Patel N, Lomaestro B, Rodvold KA, Drusano GL. Relationship between initial vancomycin concentration-time profile and nephrotoxicity among hospitalized patients. Clin Infect Dis 2009; 49:507-514
12. Drusano GL, Ambrose PG, Bhavnani SM, Bertino JS, Nafziger AN, Louie A. Back to the future: using aminoglycosides again and how to dose them optimally. Clin Infect Dis 2007; 45:753-760 (Pubitemid 47378891)
13. Scaglione F, Esposito S, Leone S, Lucini V, Panacci M, Ma L, Drusano GL. Feedback dose alteration significantly affects probability of pathogen eradication in nosocomial pneumonia. Eur Respir J 2009; 34:394-400.
14. Lodise TP, McKinnon PS, Swiderski L, Rybak MJ. Outcomes analysis of delayed antibiotic treatment for hospital-acquired Staphylococcus aureus bacteremia. Clin Infect Dis 2003; 36: 1418-1423
15. Walsh TJ, Karlsson MO, Driscoll T, et al. Pharmacokinetics and safety of intravenous voriconazole in children after single or multiple dose administration. Antimicrob Agents Chemother 2004; 48:2166-2172 (Pubitemid 38691615)
16. Karlsson MO, Lustar I, Milligan PA. Population pharmacokinetic analysis of voriconazole plasma concentration data from pediatric studies. Antimicrob Agents Chemother 2009; 53:935-944